Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
ABX 51.81 −0.8% TTS 2.50 +0.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.82 +9.7% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.45 +0.3% SGZ 0.045 +0.0% S 0.160 +33.3% GRSL 0.315 −1.6% DEX 0.395 +2.6% WMS 0.040 +0.0% EMPR 0.830 +1.2% ABX 51.81 −0.8% TTS 2.50 +0.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.82 +9.7% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.45 +0.3% SGZ 0.045 +0.0% S 0.160 +33.3% GRSL 0.315 −1.6% DEX 0.395 +2.6% WMS 0.040 +0.0% EMPR 0.830 +1.2%
M&A / Property Routine +

The Precision Peptide Company Establishes Compliant U.S. Peptide Access with Telehealth and Prescription Infrastructure Partnership

Building compliant U.S. telehealth and compounding infrastructure ahead of pivotal July FDA PCAC review.

By The Northwire Desk — AI Analysis Jun 09, 2026 · 07:31 BPC · 0.45 The Precision Peptide Company Inc.
Executive Summary
  • The Precision Peptide Company signed an agreement with a U.S.-based telehealth and infrastructure partner to enable compliant prescribing, fulfillment, and delivery of its peptide products across all 50 states.
  • This partnership complements a previously announced June 2, 2026 agreement with a U.S.-based 503A sterile compounding pharmacy, ensuring 100% of peptides (including BPC-157) are compounded domestically.
  • The initiative positions the company to scale compliant commercial operations and be ready for immediate deployment as U.S. regulatory clarity regarding peptide compounding develops.
  • The FDA's Pharmacy Compounding Advisory Committee (PCAC) is scheduled to review BPC-157 and related substances on July 23, 2026. The company is proactively building prescription-based infrastructure ahead of this date.
Material Impact
  • The announcement is a direct follow-up to the June 2 compounding agreement, addressing the "last mile" of commercialization (prescribing and telehealth fulfillment) after securing the supply chain.
  • It introduces no new revenue streams, financial terms, or unexpected partnerships. The telehealth platform is described as trusted by over 100 brands and designed to align with HIPAA and pharmacy regulations.
  • The move is strictly preparatory, ensuring the company can execute immediately if the July 23 PCAC meeting yields favorable regulatory clarity. It reduces operational friction but does not guarantee commercial success or revenue.
BPC · Price
Company Overview
  • The Precision Peptide Company focuses on peptide-based wellness and recovery therapeutics, primarily centered on BPC-157.
  • The company is developing a needle-free transdermal patch to replace traditional injectable peptide therapies, aiming to lower barriers to entry for consumers.
  • Commercial strategy includes an exclusive marketing partnership with MMA Inc., leveraging a global combat sports ecosystem of over 5 million social media followers and 800+ verified gyms.
  • The company is actively building a compliant U.S. distribution network, partnering with domestic 503A compounding pharmacies and telehealth platforms to navigate evolving FDA regulations.
Read the original news release →

More from The Precision Peptide Company Inc.

Jun 23, 2026 · 07:31

Compliance milestones unlock e-commerce scaling, but regulatory clarity remains the true catalyst.

Other Jun 11, 2026 · 17:01

Pre-revenue peptide developer secures at-market capital to fund U.S. commercial rollout amid regulatory tailwinds.

Financings Jun 02, 2026 · 07:01

The Precision Peptide Company Inc.

Financings May 26, 2026 · 07:31

Precision Peptide Advances Commercial Launch with MMA Partnership Backing

Other May 21, 2026 · 09:00

McGregor and Trump Jr. muscle into peptide marketing pact, but needle-free patch launch remains the real prize

Financings May 21, 2026 · 07:31

Precision Peptide Solidifies MMA Partnership While Regulatory Clock Ticks Toward July Review

M&A / Property